Published in BMC Med on April 04, 2013
Rare association of cutaneous vasculitis, IgA nephropathy and antiphospholipid antibody syndrome with tuberculous lymphadenitis. Clinics (Sao Paulo) (2013) 1.00
Sleep apnea and the risk of chronic kidney disease: a nationwide population-based cohort study. Sleep (2015) 0.97
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) (2014) 0.85
Autoimmunity: an underlying factor in the pathogenesis of hypertension. Curr Hypertens Rep (2014) 0.81
The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review. J Immunol Res (2015) 0.78
Novel pebbles in the mosaic of autoimmunity. BMC Med (2013) 0.76
Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis. CEN Case Rep (2014) 0.75
Increased Risk of Herpes Zoster Following Dermatomyositis and Polymyositis: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) (2015) 0.75
Protein-Losing Gastroenteropathy Associated With Sjögren's Syndrome: First Known Case Reported Outside of Asia. ACG Case Rep J (2015) 0.75
Boon and bane of remission induction with rituximab in ANCA-associated vasculitis: lessons learned from the RAVE-ITN follow-up study. J Renal Inj Prev (2013) 0.75
Does sleep apnea damage the kidneys? Sleep (2015) 0.75
Antiphospholipid antibodies and systemic scleroderma. Turk J Haematol (2013) 0.75
Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Increased risk of chronic kidney disease in patients with rosacea: A nationwide population-based matched cohort study. PLoS One (2017) 0.75
Rituximab-induced remission in a woman with coexisting rheumatoid arthritis and nephrotic syndrome. Rheumatol Int (2015) 0.75
The clinical and pathological characteristics of nephropathies in connective tissue diseases in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol (2017) 0.75
Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Front Med (Lausanne) (2017) 0.75
Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Rheumatoid arthritis. Lancet (2010) 9.37
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet (2011) 8.89
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (2001) 6.23
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 5.02
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med (2011) 4.08
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol (2009) 3.83
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum (2008) 2.63
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis (2007) 2.60
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis (2010) 2.38
Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum (2009) 2.32
Long-term outcomes of scleroderma renal crisis. Ann Intern Med (2000) 2.27
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum (2009) 2.19
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol (2009) 2.03
Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus (2008) 2.00
Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol (2008) 1.98
The use of laboratory tests in the diagnosis of SLE. J Clin Pathol (2000) 1.92
Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant (2005) 1.89
Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum (2004) 1.87
B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum (2011) 1.86
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci (2010) 1.80
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum (2007) 1.79
Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol (2006) 1.75
Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer (2001) 1.72
Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant (2001) 1.67
Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum (2009) 1.63
Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum (2011) 1.62
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant (2012) 1.58
Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum (1995) 1.55
Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol (2010) 1.53
Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford) (1999) 1.53
Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol (2004) 1.52
Updates on the treatment of lupus nephritis. J Am Soc Nephrol (2010) 1.48
Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol (2004) 1.46
Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum (1998) 1.45
Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther (2010) 1.45
The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol (1999) 1.44
Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol (1995) 1.44
Renal involvement and followup of 130 patients with primary Sjögren's syndrome. J Rheumatol (2007) 1.43
Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol (1998) 1.40
Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) (2000) 1.36
Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis (2007) 1.35
Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol (2007) 1.32
Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol (2009) 1.31
Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med (1984) 1.26
Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev (2010) 1.24
Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med (2006) 1.24
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus (2011) 1.23
The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis (2003) 1.21
Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus (2011) 1.21
The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus (2010) 1.21
Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum (2006) 1.19
Minimal change disease in systemic lupus erythematosus. Clin Nephrol (2002) 1.19
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther (2010) 1.18
Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med (2009) 1.17
Antiphospholipid antibodies and renal involvement. Am J Nephrol (2009) 1.15
Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis (2003) 1.14
Membranous glomerulonephritis in rheumatoid arthritis not related to gold or D-penicillamine therapy: a report of four cases and review of the literature. Clin Nephrol (1987) 1.13
Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 1.13
Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol (2011) 1.09
Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program (2011) 1.08
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int (2009) 1.08
Renal involvement in patients with polymyositis and dermatomyositis. Int J Clin Pract (2005) 1.06
Normotensive renal failure in systemic sclerosis. Arthritis Rheum (1989) 1.06
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum (2007) 1.06
Renal involvement in primary Sjögren's syndrome. QJM (2000) 1.06
Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol (2010) 1.05
Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum (2011) 1.03
Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) (2010) 1.03
Kidney disease in antiphospholipid syndrome. Rheum Dis Clin North Am (2006) 1.02
Sjögren's syndrome. Yonsei Med J (2003) 1.00
The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep (2011) 1.00
Hypokalemic periodic paralysis in Sjogren's syndrome secondary to distal renal tubular acidosis. Rheumatol Int (2012) 1.00
Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum (2008) 0.99
Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus (2012) 0.99
Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol Int (2011) 0.98
[Dermatomyositis associated with immune-complex type nephritis induced by tubular epithelial antigen]. Nihon Jinzo Gakkai Shi (1976) 0.96
Further description of early clinically silent lupus nephritis. Lupus (2006) 0.96
Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.96
Collapsing glomerulopathy occurring in HIV-negative patients with systemic lupus erythematosus: report of three cases and brief review of the literature. Lupus (2011) 0.96
Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol (2010) 0.94
Symptomatic renal tubular acidosis (RTA) in patients with systemic lupus erythematosus: an analysis of six cases with new association of type 4 RTA. Rheumatology (Oxford) (2005) 0.93
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus (2005) 0.93
Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement. Clin Rheumatol (2003) 0.93
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
CCR7 deficiency exacerbates injury in acute nephritis due to aberrant localization of regulatory T cells. J Am Soc Nephrol (2009) 1.79
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol (2010) 1.52
Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging Cell (2008) 1.49
A rare case of milky urine. Wien Klin Wochenschr (2010) 1.39
Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study. Wien Klin Wochenschr (2002) 1.39
Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis (2002) 1.39
Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur J Immunol (2005) 1.16
Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest (2009) 1.16
Cyclosporine A induces senescence in renal tubular epithelial cells. Am J Physiol Renal Physiol (2007) 1.08
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol (2009) 1.07
Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. Am J Physiol Renal Physiol (2007) 1.05
Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol (2014) 1.01
Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int (2003) 1.01
Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest (2004) 1.01
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Recipient and donor body mass index as important risk factors for delayed kidney graft function. Transplantation (2012) 0.98
The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol (2005) 0.98
Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant (2010) 0.96
Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics (2009) 0.96
[Remission of chronic kidney diseases. A realistic goal?]. Wien Klin Wochenschr (2003) 0.96
Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney Int (2009) 0.95
Reliability of t7-based mRNA linear amplification validated by gene expression analysis of human kidney cells using cDNA microarrays. Nephron Exp Nephrol (2004) 0.94
Eurotransplant kidney allocation system (ETKAS): rationale and implementation. Nephrol Dial Transplant (2005) 0.93
Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant (2007) 0.93
Role of alpha/beta and gamma/delta T cells in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2007) 0.93
Gene-expression profiles and age of donor kidney biopsies obtained before transplantation distinguish medium term graft function. Transplantation (2007) 0.93
Alterations in gene expression in cadaveric vs. live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. Am J Transplant (2004) 0.92
Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin d. Perit Dial Int (2010) 0.91
Effect of tissue fixatives on telomere length determination by quantitative PCR. Mech Ageing Dev (2005) 0.91
Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin Appl (2011) 0.90
Transforming omics data into context: bioinformatics on genomics and proteomics raw data. Electrophoresis (2006) 0.90
Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther (2008) 0.89
Regional variability in the incidence of end-stage renal disease: an epidemiological approach. Nephrol Dial Transplant (2003) 0.88
p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2006) 0.88
Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant (2006) 0.87
Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol (2008) 0.86
Oncostatin M is a novel inhibitor of TGF-β1-induced matricellular protein expression. Am J Physiol Renal Physiol (2011) 0.86
Age and renal transplantation: an interim analysis. Nephrol Dial Transplant (2003) 0.86
Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. Lab Invest (2009) 0.85
Blood and breath profiles of volatile organic compounds in patients with end-stage renal disease. BMC Nephrol (2014) 0.85
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) (2014) 0.85
Cigarette smoking and vascular pathology in renal biopsies. Kidney Int (2002) 0.84
The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2009) 0.84
Regular physical exercise improves endothelial function in heart transplant recipients. Clin Transplant (2002) 0.83
Oncostatin M inhibits TGF-β1-induced CTGF expression via STAT3 in human proximal tubular cells. Biochem Biophys Res Commun (2012) 0.83
Cigarette smoking and chronic allograft nephropathy. Nephrol Dial Transplant (2007) 0.83
Late referral defined by renal function: association with morbidity and mortality. J Nephrol (2004) 0.83
Detection of coregulation in differential gene expression profiles. Biosystems (2005) 0.83
Discrete simulation of regulatory homo- and heterodimerization in the apoptosis effector phase. Bioinformatics (2002) 0.82
Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism. Transplantation (2011) 0.82
Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int (2002) 0.82
Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother (2005) 0.82
Increased renal versican expression is associated with progression of chronic kidney disease. PLoS One (2012) 0.82
Linking transcriptomic and proteomic data on the level of protein interaction networks. Electrophoresis (2010) 0.82
Effect of dialysate temperature and diabetes on autonomic cardiovascular regulation during hemodialysis. Kidney Blood Press Res (2008) 0.82
Neutrophil transmigration in renal proximal tubular LLC-PK1 cells. Cell Physiol Biochem (2004) 0.82
Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. Wien Klin Wochenschr (2013) 0.82
Molecular pathways and crosstalk characterizing the cardiorenal syndrome. OMICS (2012) 0.81
Systems biology: building a useful model from multiple markers and profiles. Nephrol Dial Transplant (2012) 0.81
Effect of different immunosuppressive drugs on immune cells from young and old healthy persons. Gerontology (2014) 0.80
Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system. Nephrol Dial Transplant (2004) 0.80
Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis. J Nephrol (2004) 0.80
The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis. Int J Clin Exp Pathol (2011) 0.80
In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. Nephrol Dial Transplant (2004) 0.80
The exchangeable calcium pool: physiology and pathophysiology in chronic kidney disease. Nephrol Dial Transplant (2011) 0.80
FGF23 is associated with disease severity and prognosis in chronic heart failure. Eur J Clin Invest (2014) 0.79
Calcineurin inhibitor-based immunosuppressive therapy, donor age, and long-term outcome after kidney transplantation. Transplantation (2009) 0.79
Failure of BCL-2 up-regulation in proximal tubular epithelial cells of donor kidney biopsy specimens is associated with apoptosis and delayed graft function. Lab Invest (2002) 0.79
Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest (2015) 0.79
Biomarkers of aging with prognostic and predictive value in non-oncological diseases. Curr Med Chem (2009) 0.79
Membranous nephropathy in a patient with hereditary complete complement C4 deficiency. Nephrol Dial Transplant (2004) 0.78
ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells. J Cell Physiol (2007) 0.78
Sevelamer use and incidence of peritonitis in peritoneal dialysis. Wien Klin Wochenschr (2011) 0.78
Expression of granzyme A in human polymorphonuclear neutrophils. Immunology (2007) 0.77
Role of thrombospondin-1 in the autologous phase of an accelerated model of anti-glomerular basement membrane glomerulonephritis. Nephron Exp Nephrol (2004) 0.77
Effects of AT1 and AT2 receptor blockade on angiotensin II induced apoptosis of human renal proximal tubular epithelial cells. Wien Klin Wochenschr (2002) 0.77
A murine model of phosphate nephropathy. Am J Pathol (2011) 0.77
Impact of anemia on aortic pulse wave velocity in hemodialysis patients. Kidney Blood Press Res (2009) 0.76
Clearance of C4d deposition after successful treatment of acute humoral rejection in follow-up biopsies: a report of three cases. Transpl Int (2004) 0.76
Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect Dis (2006) 0.75
A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases. BMC Med Genomics (2014) 0.75
Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome. Int J Nephrol (2010) 0.75
Antioxidant therapy in glomerular disease. Wien Klin Wochenschr (2002) 0.75
The 9th International Wyeth Transplantation Symposium: "Phases, stages and risk factors-considering new immunosuppressive strategies for renal transplant patients." Foreword. Transplant Proc (2009) 0.75
Distal renal artery stenosis after percutaneous renal denervation leading to renal impairment but normotension. J Clin Hypertens (Greenwich) (2014) 0.75
Effects of microinjection of synthetic Bcl-2 domain peptides on apoptosis of renal tubular epithelial cells. Am J Physiol Renal Physiol (2002) 0.75
A hidden cause of angina pectoris: when ABG analysis is the only helpful diagnostic tool. Int J Cardiol (2005) 0.75
Fever of unknown origin in renal transplant patients with tacrolimus. Clin Transplant (2008) 0.75
Detrimental effects of controlled reperfusion on renal function after porcine autotransplantation are fully compensated by the use of Carolina rinse solution. Transpl Int (2003) 0.75
Medicine based on systematic research, eminence based medicine or common sense medicine--what would you prefer? EDTNA ERCA J (2006) 0.75
Evaluation of the living kidney donor. Nephrol Dial Transplant (2004) 0.75
[Primary glomerulonephritis]. Wien Klin Wochenschr (2006) 0.75
Chronic allograft failure: a disease we don't understand and can't cure? Nephrol Dial Transplant (2002) 0.75
One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients. Nephron Clin Pract (2003) 0.75
Proteinuria and hemoglobin levels in patients with primary glomerular disease. Am J Kidney Dis (2005) 0.75